Kamen Joins Third Rock Ventures

Xconomy Boston — 

Third Rock Ventures said today it has named Robert Kamen, previously of Oxford Bioscience Partners, as an entrepreneur-in-residence. Kamen’s 30 years in biologics includes time spent as president of Abbott Bioresearch Center, where was involved in the discovery of the blockbuster rheumatoid arthritis drug adalimumab (Humira), according to Third Rock. Kamen is also an alumnus of the legendary Genetics Institute, where he began his successful career. Third Rock said that Kamen, who will be based in the firm’s Boston office, is expected take part in the development of potential new companies.